Semax

Moderate Evidence

What Is Semax?

Semax is a synthetic heptapeptide consisting of seven amino acids (Met-Glu-His-Phe-Pro-Gly-Pro) developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s. It is a synthetic analogue of the adrenocorticotropic hormone (ACTH) fragment 4-10, extended with a Pro-Gly-Pro sequence that enhances metabolic stability and prolongs biological activity [1].

The peptide was designed to retain the neurotrophic and nootropic properties of the ACTH 4-10 fragment while eliminating the hormonal (steroidogenic) effects of the parent ACTH molecule. Research indicates that semax does not influence adrenal cortisol secretion, making it functionally distinct from ACTH despite its structural relationship [2].

Semax has been approved in Russia and Ukraine for the treatment of stroke, transient ischaemic attack, cognitive disorders, peptic ulcer disease, and optic nerve atrophy. It is marketed as a 0.1% and 1% intranasal solution. Outside of Russia and Ukraine, semax is not approved for human therapeutic use by the FDA, MHRA, TGA, or other major regulatory bodies. Individuals considering semax should consult a qualified healthcare provider and understand the regulatory landscape in their jurisdiction.

Mechanism of Action

Research suggests semax exerts its neurotropic effects through several interconnected pathways:

BDNF and neurotrophic factor upregulation. One of the most consistently observed effects in preclinical research is semax’s ability to increase the expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in the hippocampus and cortex [3]. BDNF plays a critical role in neuronal survival, synaptic plasticity, and the formation of new neural connections, making it central to learning and memory processes.

Dopaminergic and serotonergic modulation. Animal studies indicate that semax may modulate dopamine and serotonin turnover in brain regions associated with attention, motivation, and cognitive processing [4]. Research suggests that semax may stabilise monoamine levels without producing the stimulatory or euphoric effects associated with direct dopamine agonists.

Neuroprotective mechanisms. Studies in animal models of cerebral ischaemia suggest that semax may reduce infarct volume and preserve neuronal viability through anti-inflammatory and anti-apoptotic mechanisms [5]. Research indicates the peptide may reduce the expression of pro-inflammatory cytokines and inhibit caspase-mediated cell death pathways in neural tissue.

Gene expression modulation. Transcriptomic studies have revealed that semax administration influences the expression of hundreds of genes in brain tissue, including those involved in neurotransmitter signalling, immune response, and vascular function [6]. This broad transcriptomic effect suggests a multifactorial mechanism rather than a single molecular target.

Research and Evidence

Cognitive Enhancement

The nootropic effects of semax have been studied in both animal models and human clinical trials. Russian clinical studies have evaluated semax in patients with cognitive impairment following stroke and in healthy volunteers under conditions of cognitive stress.

A clinical study by Kaplan et al. (2004) in patients recovering from ischaemic stroke reported significant improvements in cognitive function scores, including attention, memory, and executive function, following intranasal semax treatment compared to standard care alone [7]. Studies in healthy volunteers under conditions of prolonged cognitive load have also reported improvements in sustained attention and working memory [2].

Animal research has consistently demonstrated that semax enhances performance in learning and memory paradigms, including the Morris water maze and passive avoidance tests [3]. These effects are hypothesised to be mediated primarily through BDNF upregulation in the hippocampus.

Neuroprotection and Stroke Recovery

Semax’s most clinically validated application is in the context of cerebrovascular disease. Russian clinical trials have evaluated semax as an adjunctive treatment for acute ischaemic stroke and transient ischaemic attack.

Research by Gusev et al. (1997) reported that intranasal semax administration within the first 12 hours of ischaemic stroke onset, in addition to standard treatment, was associated with improved neurological outcomes and accelerated recovery compared to standard treatment alone [5]. The peptide is approved in Russia for this indication based on accumulated clinical evidence.

Preclinical studies suggest that the neuroprotective effects may involve reduction of oxidative stress, modulation of inflammatory cascades, and preservation of blood-brain barrier integrity following ischaemic injury [8].

BDNF Modulation

The ability of semax to upregulate BDNF expression represents one of its most compelling research findings. Studies in rodent models have shown significant increases in BDNF mRNA and protein levels in the hippocampus and basal forebrain following semax administration [3][6]. Given BDNF’s established role in synaptic plasticity, neurogenesis, and neuroprotection, this mechanism may underlie many of semax’s observed cognitive and neuroprotective effects.

Dosage and Administration

Important: The following information reflects dosages from the approved Russian formulation and community protocols. Semax is not approved outside of Russia and Ukraine, and no international dosing guidelines exist. Always consult a qualified healthcare provider before considering any peptide protocol.

Common Research and Community-Reported Protocols

• Intranasal spray (0.1% solution): 200-600 mcg per day, divided into 2-3 administrations. The approved Russian formulation delivers 50 mcg per drop. This is the most widely studied and commonly referenced route.
• High-concentration formulation (1% solution): Used in Russian clinical practice for acute neurological conditions, delivering approximately 500 mcg per drop. This concentration is reserved for specific clinical indications under medical supervision.
• Subcutaneous injection: 200-600 mcg per day. Less commonly referenced than the intranasal route but reported in some community protocols.

Administration Notes

Intranasal administration is the standard route, providing direct access to the central nervous system via the olfactory pathway. The nasal mucosa allows for relatively rapid absorption without first-pass hepatic metabolism.

Cycling

Russian clinical protocols typically use treatment courses of 10-14 days. Community protocols often reference similar durations with rest periods between courses. Extended continuous use has not been comprehensively evaluated.

Side Effects and Safety

Semax has demonstrated a favourable safety profile across Russian clinical trials and post-marketing surveillance.

Observed in clinical studies: Russian clinical data reports a low incidence of adverse effects at approved doses. Semax has not shown evidence of toxicity, mutagenicity, or teratogenicity in preclinical safety studies [1][9]. Importantly, semax does not influence adrenal cortisol production despite its structural derivation from ACTH.

Community-reported side effects (anecdotal, not clinically validated):

• Mild nasal irritation or dryness with intranasal use
• Transient headache
• Hair shedding (reported by some users, mechanism unclear)
• Mild irritability or emotional sensitivity
• Occasional dizziness

Potential concerns and unknowns:

• Long-term safety data beyond the durations studied in Russian clinical practice is limited
• Drug interactions have not been comprehensively characterised in international studies
• Effects during pregnancy and lactation have not been adequately studied; use should be avoided
• The quality and purity of research-grade semax available outside of Russia may vary
• Individuals with a history of seizure disorders should exercise caution, as BDNF modulation may theoretically influence seizure threshold

Frequently Asked Questions

How does semax compare to selank?

Semax and selank are both developed at the same Russian research institute and share the Pro-Gly-Pro stabilising tail. However, they derive from different parent molecules and have distinct primary effects. Semax, derived from ACTH 4-10, primarily targets cognitive enhancement and neuroprotection. Selank, derived from tuftsin, primarily targets anxiety reduction and immune modulation. Some community protocols combine both peptides for complementary effects, though this combination has not been formally evaluated in controlled clinical trials.

Does semax affect cortisol levels?

Despite being derived from ACTH, research consistently shows that semax does not stimulate adrenal cortisol secretion [2]. The structural modifications that create semax from the ACTH 4-10 fragment effectively separate the neurotrophic properties from the hormonal effects of the parent molecule.

How quickly does semax take effect?

Russian clinical data suggests that cognitive effects may be noticed within the first few days of treatment, with more substantial improvements developing over a 10-14 day course [7]. The intranasal route provides relatively rapid absorption, and acute effects on attention have been reported within 30-60 minutes of administration in some studies.

Is semax approved for medical use anywhere?

Semax is approved in Russia and Ukraine for several indications including ischaemic stroke, transient ischaemic attack, cognitive disorders, and optic nerve atrophy. It is not approved by the FDA, MHRA, TGA, EMA, or other major international regulatory agencies. The clinical evidence base, while substantial within the Russian medical literature, has been generated primarily within Russian research and regulatory frameworks.

Can semax be taken long-term?

Long-term continuous use of semax has not been comprehensively studied. Russian clinical protocols typically employ treatment courses of 10-14 days. Some clinicians in Russia prescribe repeated courses with intervals between them. The safety and efficacy of continuous long-term use remains an open question requiring further research [9].

References

References

1. Ashmarin IP, et al. Regulatory peptides derived from prohormones: the concept and development of peptide-based drugs (semax). Neuroscience and Behavioral Physiology. 1995;25(4):312-318.
2. Aseev IV, et al. Semax: mechanisms of action and clinical applications. Zhurnal Nevrologii i Psikhiatrii. 2007;107(1):35-41.
3. Dolotov OV, et al. Semax, an ACTH (4-10) analogue with nootropic properties, activates BDNF and trkB gene expression in rat hippocampus. Brain Research. 2006;1117(1):54-60.
4. Eremin KO, et al. Semax effects on dopaminergic activity in the rat brain. Doklady Biological Sciences. 2005;405(1):466-468.
5. Gusev EI, et al. Neuroprotective effects of semax in acute cerebral ischaemia. Zhurnal Nevrologii i Psikhiatrii. 1997;97(6):26-34.
6. Agapova TY, et al. Transcriptomic analysis of semax effects on gene expression in the rat brain. Doklady Biochemistry and Biophysics. 2007;417(1):317-320.
7. Kaplan AY, et al. Semax effects on cognitive function in patients recovering from ischaemic stroke. Zhurnal Nevrologii i Psikhiatrii. 2004;104(2):22-28.
8. Filippenkov IB, et al. Neuroprotective and anti-inflammatory mechanisms of semax in rat models of cerebral ischaemia. Frontiers in Neuroscience. 2019;13:708.
9. Levitskaya NG, et al. Safety profile and pharmacological properties of semax: a comprehensive review. Eksperimental'naya i Klinicheskaya Farmakologiya. 2008;71(2):56-63.
10. Medvedeva EV, et al. Semax modulates the expression of neurotrophins and their receptors in the rat brain. Neuroscience Letters. 2013;550:121-125.

Continue Reading

Readers also explore

All peptides →

Cognitive

Selank

Selank (TP-7)

anxiety reduction · cognitive enhancement · immune modulation

Open profile